指南与共识类风湿关节炎脊柱关节炎系统性红斑狼疮

2022年美国风湿病学会指南:风湿性和肌肉骨骼疾病患者的疫苗接种

2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases.
指南 / 共识 · Arthritis Rheumatol · 2023-01-04

该指南针对儿童和成人风湿性和肌肉骨骼疾病(RMD)患者,采用GRADE方法制定疫苗接种推荐。指南扩展了部分疫苗的适应证,并给出是否暂停免疫抑制药物或延迟接种以最大化疫苗免疫原性和效力的指导,多数推荐为条件性且证据质量低。

要点

  • 指南扩展了部分疫苗在RMD患者中的适应证。
  • 指南涉及是否暂停免疫抑制药物或延迟接种以最大化疫苗免疫原性和效力。
  • 多数推荐为条件性且支持证据质量低。

核心结论

  • 应用这些推荐时应考虑患者对疫苗可预防疾病的个体风险和对疾病复发的风险,特别是为接种疫苗而暂停免疫抑制药物时。
  • 鼓励在临床环境中与患者共同决策。

研究设计与样本

  • 该指南遵循美国风湿病学会(ACR)的利益冲突管理政策和指南制定流程,包括推荐分级的评估、制定与评价(GRADE)方法,并遵循指南研究与评价(AGREE)标准。
  • 由成人和儿童风湿病学家及指南方法学家组成的核心领导团队起草了临床人群、干预、对照、结局(PICO)问题。
  • 审查团队针对PICO问题进行系统文献综述,对证据质量进行分级,并生成证据报告。
  • 由成人和儿童风湿病提供者、感染病专家和患者代表组成的专家投票小组审查证据并制定推荐,每条推荐的方向和强度需达到≥70%的共识。

主要发现

  • 该指南纳入了部分疫苗在RMD患者中扩展的适应证。
  • 该指南提供了关于是否暂停免疫抑制药物或延迟接种以最大化疫苗免疫原性和效力的指导。
  • 该指南还涉及正在使用免疫抑制药物的患者使用减毒活疫苗的安全方法。
  • 大多数推荐为条件性推荐,且支持证据质量低。

关键数值与推荐

  • 每条推荐的方向和强度需达到≥70%的共识。
  • 大多数推荐为条件性推荐,且支持证据质量低。

临床怎么用

  • 应用这些推荐时应考虑患者对疫苗可预防疾病的个体风险和对疾病复发的风险,特别是为接种疫苗而暂停免疫抑制药物时。
  • 鼓励在临床环境中与患者共同决策。

局限性

  • 大多数推荐为条件性推荐,且支持证据质量低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To provide evidence-based recommendations on the use of vaccinations in children and adults with rheumatic and musculoskeletal diseases (RMDs). METHODS: This guideline follows American College of Rheumatology (ACR) policy guiding management of conflicts of interest and disclosures and the ACR guideline development process, which includes the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology. It also adheres to the Appraisal of Guidelines for Research and Evaluation (AGREE) criteria. A core leadership team consisting of adult and pediatric rheumatologists and a guideline methodologist drafted clinical population, intervention, comparator, outcomes (PICO) questions. A review team performed a systematic literature review for the PICO questions, graded the quality of evidence, and produced an evidence report. An expert Voting Panel reviewed the evidence and formulated recommendations. The panel included adult and pediatric rheumatology providers, infectious diseases specialists, and patient representatives. Consensus required ≥70% agreement on both the direction and strength of each recommendation. RESULTS: This guideline includes expanded indications for some vaccines in patients with RMDs, as well as guidance on whether to hold immunosuppressive medications or delay vaccination to maximize vaccine immunogenicity and efficacy. Safe approaches to the use of live attenuated vaccines in patients taking immunosuppressive medications are also addressed. Most recommendations are conditional and had low quality of supporting evidence. CONCLUSION: Application of these recommendations should consider patients' individual risk for vaccine-preventable illness and for disease flares, particularly if immunosuppressive medications are held for vaccination. Shared decision-making with patients is encouraged in clinical settings.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Bass AR, Chakravarty E, Akl EA, et al. 2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol. 2023. PMID: 36597810. doi:10.1002/art.42386

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。